Medinotec Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $9.7M | $9.1M | $5.0M | $999.6K | $1.0M |
| Cost of Revenue | $4.6M | $4.3M | $-2.6M | $-417.8K | $585.1K |
| Gross Profit | $5.1M | $4.8M | $2.4M | $581.8K | $455.2K |
| Gross Margin | 52.7% | 52.9% | 48.7% | 58.2% | 43.8% |
| Operating Expenses | |||||
| Research & Development | $149.9K | $91.1K | $-22.4K | $-64.9K | $34.8K |
| SG&A Expense | $2.3M | $1.3M | $-1.7M | $-648.2K | $498.2K |
| Operating Income | $1.1M | $3.2M | $600.6K | $-238.6K | $-190.6K |
| Operating Margin | 11.2% | 35.0% | 12.0% | -23.9% | -18.3% |
| Interest Expense | $87.6K | $176.4K | $-277.2K | $-226.8K | — |
| Pretax Income | $1.1M | $3.0M | $-253.8K | $-391.5K | $-189.0K |
| Income Tax Expense | $-274.7K | $-864.7K | $-150.9K | $38.7K | $-65.0K |
| Net Income | $794.5K | $2.2M | $-404.7K | $-352.7K | $-124.0K |
| Net Margin | 8.2% | 23.7% | -8.1% | -35.3% | -11.9% |
| EPS (Basic) | $0.07 | $0.18 | $-0.03 | $-0.03 | $0.01 |
| EPS (Diluted) | — | — | — | — | — |
| Shares Outstanding (Basic) | 11.8M | 11.7M | 11.7M | 11.7M | 10.0M |
| Shares Outstanding (Diluted) | 11.8M | 11.7M | 11.7M | 11.7M | 10.0M |
| Dividends Per Share | — | — | — | — | — |